Wilson Therapeutics AB (publ) Interim Report January 1 – June 30, 2016
Encouraging preliminary data from ongoing clinical trialApril 1 – June 30, 2016 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 26.9 M (loss: 16.7) · Loss per share, before and after dilution, totaled SEK 1.66 (loss: 13.14) · At June 30, cash and cash equivalents amounted to SEK 435.6 M (26.8) January 1 – June 30, 2016 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 49.2 M (loss: 30.5) · Loss per share, before and after dilution, totaled SEK 5.86 (loss: 24.07) Significant events during the period January 1 – June 30,